Europe Omega-3 Ingredients for Pharmaceuticals Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Aug 2020
  • Europe
  • 350 Pages
  • No of Tables: 234
  • No of Figures: 45

Europe Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Sweden, Denmark, Poland, Turkey and Rest of Europe) Industry Trends and Forecast to 2027       

Europe Omega-3 Ingredients For Pharmaceuticals Market Market Analysis and Insights: Europe Omega-3 Ingredients for Pharmaceuticals Market  

Omega-3 ingredients for pharmaceuticals market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.1% in the forecast period of 2020 to 2027 and is expected to reach USD 260,563.23 thousand by 2027. Enormous health benefits of omega-3 and growing demand of functional and supplement food are the major drivers which propelled the demand of the omega-3 ingredients for pharmaceuticals market in the forecast period.

Omega-3 ingredients for pharmaceuticals comprises features such as increasing preferences towards certified food ingredients will impact in launching new product by the manufacturers into the omega-3 ingredients for pharmaceuticals market which enhance its demand as well as rising burden of lifestyle diseases leads the demand of omega-3 based products and have enhanced the demand of omega-3 ingredients for pharmaceuticals market.

Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative omega-3 ingredients for pharmaceuticals which is expected to provide various other opportunities in the omega-3 ingredients for pharmaceuticals market. However, high cost of product and negative consumer perception about the smell and taste of omega-3 ingredients for pharmaceuticals is expected to restraint the omega-3 ingredients for pharmaceuticals market growth in the forecast period.   

The omega-3 ingredients for pharmaceuticals market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the omega-3 ingredients for pharmaceuticals market scenario contact Data Bridge Market Research for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.    

Europe Omega-3 Ingredients For Pharmaceuticals Market Europe Omega-3 Ingredients for Pharmaceuticals Market Scope and Market Size

Omega-3 ingredients for pharmaceuticals market are segmented on the basis of source, type, forms, therapeutic areas, population type, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

  • On the basis of source, the omega-3 ingredients for pharmaceuticals market is segmented into marine and plant. In 2020, marine segment is expected to dominate the omega-3 ingredients for pharmaceuticals market due to presence of higher proportion of good content omega-3 components in marine fish. For addition, other aquatic species including corals, worms and mollusks are often used for the production of omega-3 ingredients for different medicinal applications.
  • On the basis of type, the omega-3 ingredients for pharmaceuticals market are segmented into docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), alpha-linolenic acid (ALA). In 2020, docosahexaenoic acid (DHA) segment is dominating the omega-3 ingredients for pharmaceuticals market as this plays a key function in the growth of brains and in the control of heart disease. It is also rich in fish, whale blubber and algae, among others, which serve as another element responsible for its supremacy.
  • On the basis of forms, the omega-3 ingredients for pharmaceuticals market are segmented into dry and liquid. In 2020, the liquid segment is dominating the omega-3 ingredients for pharmaceuticals market as most of the omega-3 ingredients are obtained in liquid form. In fact, liquid form is favored over other formulations for many end-user uses in the pharmaceutical industry.
  • On the basis of therapeutic areas, the omega-3 ingredients for pharmaceuticals market are segmented into ophthalmic disorders, neurological disorders, cardiovascular diseases, autoimmune diseases, cancer, bone & joint disorders, skin health and others. In 2020, cardiovascular diseases segment is dominating the omega-3 ingredients for pharmaceuticals market because of the applications of omega-3 fatty acids in decreasing triglycerides, lowering blood pressure slightly, decreasing risk of strokes, reducing blood clotting and reducing irregular heartbeats.
  • On the basis of population type, the omega-3 ingredients for pharmaceuticals market are segmented into children and adults. In 2020, adults segment is dominating the omega-3 ingredients for pharmaceuticals market as adults are more prone to cardiovascular disease and prefers pharmaceutical products rich in omega-3 ingredients in order to cure several problems causing severe cardiovascular disease.
  • On the basis of distribution channel, the omega-3 ingredients for pharmaceuticals market are segmented into direct and indirect. In 2020, direct segment is dominating the omega-3 ingredients for pharmaceuticals market as it is the primary source of procurement by pharmaceutical companies. Moreover, pharmaceutical companies demands high quality ingredients and do not want to take risk on the same. Procurement of ingredients through direct channels is highly cost effective for healthcare providers as they are bought in bulk under terms of contract for service.  

Omega-3 Ingredients for Pharmaceuticals Market Country Level Analysis

The omega-3 ingredients for pharmaceuticals market is analyzed and market size information is provided by country, source, type, forms, therapeutic areas, population type, and distribution channel as referenced above.

The countries covered in the omega-3 ingredients for pharmaceuticals market report are the Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Sweden, Denmark, Poland, Turkey and rest of Europe.  

Germany is dominating the European omega-3 ingredients for pharmaceuticals market owing to increasing demand of functional and supplements food along with the increasing prevalence of chronic diseases across the globe.

The country section of the report also provides individual omega-3 ingredients for pharmaceuticals market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. 

Rising Burden of Lifestyle Diseases leads the Demand of Omega-3 based Products and are boosting Omega-3 Ingredients for Pharmaceuticals Market

Omega-3 ingredients for pharmaceuticals market also provides you with detailed market analysis for every country growth in omega-3 ingredients for pharmaceuticals industry with omega-3 ingredients for pharmaceuticals sales, impact of advancement in the omega-3 ingredients for pharmaceuticals treatment technology and changes in regulatory scenarios with their support for the omega-3 ingredients for pharmaceuticals market. The data is available for historic period 2010 to 2018.   

Competitive Landscape and Omega-3 Ingredients for Pharmaceuticals Market Share Analysis

Omega-3 ingredients for pharmaceuticals market competitive landscape provide details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to omega-3 ingredients for pharmaceuticals market.

The major companies which are dealing in the Europe omega-3 ingredients for pharmaceuticals market report are Novasep, KD Pharma Group, BASF SE, Corbion, DSM, AstraZeneca, GlaxoSmithKline plc, Croda International Plc, AMARIN CORPORATION, ANI Pharmaceuticals, Inc., Epax (a subsidiary of Pelagia AS), Strides Pharma Science Limited, Pharma Marine AS, Solutex, AbbVie Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the omega-3 ingredients for pharmaceuticals market.

For instance,

  • In May, 2020 DSM launched a plant based DHA oil product, DHA SF55-O200DS oil extracted from schizochytrium algae. This product is used for boosting the nutrition in mothers and infants. This new product launch by DSM increased its product portfolio in nutrition business thereby, increased demand for its product in the market leading to increased revenue in future.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the omega-3 ingredients for pharmaceuticals market which also provides the benefit for organization to improve their offering for omega-3 ingredients for pharmaceuticals.  

Customization Available: Europe Omega-3 Ingredients for Pharmaceuticals Market 

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 THE PRICE RANGE OF OMEGA-3 INGREDIENTS

TABLE 2 COST COMPARISION OF MARINE SOURCES OF OMEGA-3 INGREDIENTS

TABLE 3 COST OF PRODUCTS

TABLE 4 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 5 EUROPE MARINE IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 6 EUROPE PLANT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 7 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 8 EUROPE DOCOSAHEXAENOIC ACID (DHA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 9 EUROPE EICOSAPENTAENOIC ACID (EPA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 10 EUROPE ALPHA-LINOLENIC ACID (ALA)IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 11 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM , 2017-2026 (USD THOUSANDS)

TABLE 12 EUROPE LIQUID IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 13 EUROPE DRY IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 14 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 15 EUROPE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 16 EUROPE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 17 EUROPE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 18 EUROPE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 19 EUROPE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 20 EUROPE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 21 EUROPE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 22 EUROPE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 23 EUROPE BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 24 EUROPE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 25 EUROPE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 26 EUROPE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 27 EUROPE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 28 EUROPE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 29 EUROPE OTHERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 30 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 31 GLOBA ADULT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 32 EUROPE ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 33 GLOBA CHILDREN IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)

TABLE 34 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 35 EUROPE DIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 36 EUROPE INDIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)

TABLE 37 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY COUNTRY, 2018-2027 (USD THOUSANDS)

TABLE 38 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 39 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 40 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 41 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 42 EUROPE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 43 EUROPE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 44 EUROPE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 45 EUROPE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 46 EUROPE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 47 EUROPE BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 48 EUROPE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 49 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 50 EUROPE ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 51 EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 52 GERMANY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 53 GERMANY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 54 GERMANY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 55 GERMANY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 56 GERMANY OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 57 GERMANY NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 58 GERMANY CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 59 GERMANY AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 60 GERMANY CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 61 GERMANY BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 62 GERMANY SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 63 GERMANY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 64 GERMANY ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 65 GERMANY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 66 U.K OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 67 U.K OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 68 U.K OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 69 U.K OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 70 U.K OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 71 U.K NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 72 U.K CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 73 U.K AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 74 U.K CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 75 U.K BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 76 U.K SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 77 U.K OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 78 U.K ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 79 U.K OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 80 FRANCE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 81 FRANCE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 82 FRANCE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 83 FRANCE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 84 FRANCE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 85 FRANCE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 86 FRANCE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 87 FRANCE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 88 FRANCE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 89 FRANCE BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 90 FRANCE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 91 FRANCE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 92 FRANCE ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 93 FRANCE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 94 NETHERLANDS OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 95 NETHERLANDS OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 96 NETHERLANDS OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 97 NETHERLANDS OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 98 NETHERLANDS OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 99 NETHERLANDS NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 100 NETHERLANDS CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 101 NETHERLANDS AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 102 NETHERLANDS CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 103 NETHERLANDS BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 104 NETHERLANDS SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 105 NETHERLANDS OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 106 NETHERLANDS ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 107 NETHERLANDS OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 108 ITALY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 109 ITALY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 110 ITALY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 111 ITALY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 112 ITALY OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 113 ITALY NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 114 ITALY CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 115 ITALY AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 116 ITALY CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 117 ITALY BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 118 ITALY SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 119 ITALY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 120 ITALY ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 121 ITALY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 122 DENMARK OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 123 DENMARK OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 124 DENMARK OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 125 DENMARK OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 126 DENMARK OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 127 DENMARK NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 128 DENMARK CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 129 DENMARK AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 130 DENMARK CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 131 DENMARK BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 132 DENMARK SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 133 DENMARK OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 134 DENMARK ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 135 DENMARK OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 136 SWEDEN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 137 SWEDEN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 138 SWEDEN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 139 SWEDEN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 140 SWEDEN OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 141 SWEDEN NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 142 SWEDEN CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 143 SWEDEN AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 144 SWEDEN CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 145 SWEDEN BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 146 SWEDEN SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 147 SWEDEN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 148 SWEDEN ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 149 SWEDEN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 150 SPAIN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 151 SPAIN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 152 SPAIN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 153 SPAIN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 154 SPAIN OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 155 SPAIN NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 156 SPAIN CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 157 SPAIN AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 158 SPAIN CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 159 SPAIN BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 160 SPAIN SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 161 SPAIN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 162 SPAIN ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 163 SPAIN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 164 SWITZERLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 165 SWITZERLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 166 SWITZERLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 167 SWITZERLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 168 SWITZERLAND OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 169 SWITZERLAND NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 170 SWITZERLAND CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 171 SWITZERLAND AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 172 SWITZERLAND CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 173 SWITZERLAND BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 174 SWITZERLAND SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 175 SWITZERLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 176 SWITZERLAND ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 177 SWITZERLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 178 RUSSIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 179 RUSSIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 180 RUSSIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 181 RUSSIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 182 RUSSIA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 183 RUSSIA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 184 RUSSIA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 185 RUSSIA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 186 RUSSIA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 187 RUSSIA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 188 RUSSIA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 189 RUSSIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 190 RUSSIA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 191 RUSSIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 192 BELGIUM OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 193 BELGIUM OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 194 BELGIUM OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 195 BELGIUM OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 196 BELGIUM OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 197 BELGIUM NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 198 BELGIUM CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 199 BELGIUM AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 200 BELGIUM CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 201 BELGIUM BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 202 BELGIUM SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 203 BELGIUM OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 204 BELGIUM ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 205 BELGIUM OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 206 TURKEY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 207 TURKEY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 208 TURKEY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 209 TURKEY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 210 TURKEY OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 211 TURKEY NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 212 TURKEY CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 213 TURKEY AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 214 TURKEY CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 215 TURKEY BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 216 TURKEY SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 217 TURKEY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 218 TURKEY ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 219 TURKEY OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 220 POLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

TABLE 221 POLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)

TABLE 222 POLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)

TABLE 223 POLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 224 POLAND OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 225 POLAND NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 226 POLAND CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 227 POLAND AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 228 POLAND CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 229 POLAND BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 230 POLAND SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)

TABLE 231 POLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 232 POLAND ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)

TABLE 233 POLAND OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)

TABLE 234 REST OF EUROPE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions